Correlation Between Edgewise Therapeutics and Eledon Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Edgewise Therapeutics and Eledon Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Edgewise Therapeutics and Eledon Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Edgewise Therapeutics and Eledon Pharmaceuticals, you can compare the effects of market volatilities on Edgewise Therapeutics and Eledon Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Edgewise Therapeutics with a short position of Eledon Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Edgewise Therapeutics and Eledon Pharmaceuticals.

Diversification Opportunities for Edgewise Therapeutics and Eledon Pharmaceuticals

0.64
  Correlation Coefficient

Poor diversification

The 3 months correlation between Edgewise and Eledon is 0.64. Overlapping area represents the amount of risk that can be diversified away by holding Edgewise Therapeutics and Eledon Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eledon Pharmaceuticals and Edgewise Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Edgewise Therapeutics are associated (or correlated) with Eledon Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eledon Pharmaceuticals has no effect on the direction of Edgewise Therapeutics i.e., Edgewise Therapeutics and Eledon Pharmaceuticals go up and down completely randomly.

Pair Corralation between Edgewise Therapeutics and Eledon Pharmaceuticals

Given the investment horizon of 90 days Edgewise Therapeutics is expected to under-perform the Eledon Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Edgewise Therapeutics is 2.77 times less risky than Eledon Pharmaceuticals. The stock trades about -0.12 of its potential returns per unit of risk. The Eledon Pharmaceuticals is currently generating about 0.19 of returns per unit of risk over similar time horizon. If you would invest  317.00  in Eledon Pharmaceuticals on August 23, 2024 and sell it today you would earn a total of  90.00  from holding Eledon Pharmaceuticals or generate 28.39% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Edgewise Therapeutics  vs.  Eledon Pharmaceuticals

 Performance 
       Timeline  
Edgewise Therapeutics 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Edgewise Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Edgewise Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.
Eledon Pharmaceuticals 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Eledon Pharmaceuticals are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of very weak fundamental indicators, Eledon Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.

Edgewise Therapeutics and Eledon Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Edgewise Therapeutics and Eledon Pharmaceuticals

The main advantage of trading using opposite Edgewise Therapeutics and Eledon Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Edgewise Therapeutics position performs unexpectedly, Eledon Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eledon Pharmaceuticals will offset losses from the drop in Eledon Pharmaceuticals' long position.
The idea behind Edgewise Therapeutics and Eledon Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Other Complementary Tools

ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Stocks Directory
Find actively traded stocks across global markets